Search alternatives:
step decrease » sizes decrease (Expand Search), teer decrease (Expand Search), we decrease (Expand Search)
nn decrease » _ decrease (Expand Search), gy decreased (Expand Search), b1 decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
4 mean » _ mean (Expand Search), a mean (Expand Search), i mean (Expand Search)
Showing 181 - 200 results of 122,906 for search '(( 4 mean decrease ) OR ( 5 ((((step decrease) OR (nn decrease))) OR (a decrease)) ))', query time: 1.57s Refine Results
  1. 181
    Carbidopa decreases number of pathogenic CD4+ T cells during EAE.

    Carbidopa decreases number of pathogenic CD4+ T cells during EAE. by Huabin Zhu (594342)

    Published 2017
    Save to List
    Saved in:
  2. 182
    HPV16 PsV infection decreases following SLPI treatment or anti-annexin A2 antibody inhibition of A2t.

    HPV16 PsV infection decreases following SLPI treatment or anti-annexin A2 antibody inhibition of A2t. by Andrew W. Woodham (140650)

    Published 2012
    Save to List
    Saved in:
  3. 183
    Level of phosphorylated syndecan-4 regulates NFAT activation and is decreased by calcineurin.

    Level of phosphorylated syndecan-4 regulates NFAT activation and is decreased by calcineurin. by Alexandra V. Finsen (193861)

    Published 2011
    Save to List
    Saved in:
  4. 184
    Infection decreases short chain phospholipids in the intestines of <i>V</i>. <i>cholerae</i>-infected flies.

    Infection decreases short chain phospholipids in the intestines of <i>V</i>. <i>cholerae</i>-infected flies. by Audrey S. Vanhove (4090594)

    Published 2017
    Save to List
    Saved in:
  5. 185
    IL-35 decreased the prevalence of Th17 in CD4+ T cells.

    IL-35 decreased the prevalence of Th17 in CD4+ T cells. by Yin Zongyi (3111660)

    Published 2017
    “…<p>(A)The ratio of Th17 in CD4+ T cells. (B) Representative diagram showing Th17’s ratio in CD4+ T cells was significantly decreased in the IL-35 group compared to that in the control group (0.3% vs. 7.2% on day 5, P<0.01). …”
    Save to List
    Saved in:
  6. 186
    Pretreatment with Pam3CSK4 decreases inflammatory cytokine production.

    Pretreatment with Pam3CSK4 decreases inflammatory cytokine production. by Yi-Guo Chen (593833)

    Published 2016
    Save to List
    Saved in:
  7. 187
    The substitution F447L is adaptive for J4<sub>S52-HVR1</sub>, while it decreases infectivity of parental J4 and J4<sub>ΔHVR1</sub> HCVcc.

    The substitution F447L is adaptive for J4<sub>S52-HVR1</sub>, while it decreases infectivity of parental J4 and J4<sub>ΔHVR1</sub> HCVcc. by Christina Holmboe Olesen (11154333)

    Published 2021
    Save to List
    Saved in:
  8. 188
    Damsin (D) and ambrosin (A) treatment decreases the CSC population.

    Damsin (D) and ambrosin (A) treatment decreases the CSC population. by Wendy Soria Sotillo (4408105)

    Published 2017
    Save to List
    Saved in:
  9. 189
    BoNT/A (3.5 U/kg) decreases orofacial formalin-induced dural extravasation.

    BoNT/A (3.5 U/kg) decreases orofacial formalin-induced dural extravasation. by Boris Filipović (336089)

    Published 2013
    Save to List
    Saved in:
  10. 190
    Blocking C5L2 decreased C5a-primed neutrophils expression of membrane-bound PR3 (mPR3).

    Blocking C5L2 decreased C5a-primed neutrophils expression of membrane-bound PR3 (mPR3). by Jian Hao (160736)

    Published 2013
    Save to List
    Saved in:
  11. 191
    Differentially regulated genes in cells with increased or decreased expression of miR-106a-5p.

    Differentially regulated genes in cells with increased or decreased expression of miR-106a-5p. by Feng Zhi (294362)

    Published 2013
    “…(C) A Venn diagram of the overlap of altered genes with increased or decreased miR-106a-5p expression. …”
    Save to List
    Saved in:
  12. 192
    Full-length PRR expression increases and sPRR secretion decreases in the absence of PACE4 in mouse.

    Full-length PRR expression increases and sPRR secretion decreases in the absence of PACE4 in mouse. by Amro H. Mohammad (15081540)

    Published 2023
    Save to List
    Saved in:
  13. 193
    APB5, but not APA5, decreases proliferating cell numbers in inter-alveolar spaces of lungs.

    APB5, but not APA5, decreases proliferating cell numbers in inter-alveolar spaces of lungs. by Masami Kishi (6167105)

    Published 2018
    Save to List
    Saved in:
  14. 194
    Study Flow Diagram.

    Study Flow Diagram. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  15. 195
    Antibody and antigen responses to Lufotrelvir vs placebo day 1–90.

    Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  16. 196
    Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments).

    Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  17. 197
    Antibody and antigen responses to Ensovibep vs placebo day 1–90.

    Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  18. 198
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  19. 199
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  20. 200
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:

Search Tools: